28 July 2026 Q2 Results & Accelerate Growth gsk.com Q2 Results and Accelerate Growth Agenda Time Section Speakers 14.00 – 14.10 Q2 Results Luke Miels, Chief Executive Officer (CEO) Nina Mojas, President Global Product Strategy Deborah Waterhouse,…
28 July 2026
Q2 Results &
Accelerate Growth
gsk.com
Q2 Results and Accelerate Growth Agenda
Time
Section
Speakers
14.00 – 14.10
Q2 Results
Luke Miels, Chief Executive Officer (CEO)
Nina Mojas, President Global Product Strategy
Deborah Waterhouse, CEO, ViiV Healthcare, President Global Health
Julie Brown, Chief Financial Officer (CFO)
14.10 – 14.45
Accelerate Growth Part 1
14.45 – 15.15
Q&A
15.15 – 15.35
20-minute break
15.35 – 16.20
Accelerate Growth Part 2
16.20 – 16.55
Q&A
17.00
Adjourn / drinks reception
Introduction and objectives
Accelerate late-stage R&D
Oncology
Respiratory & Hepatology
Vaccines
HIV
Accelerate Growth programme
Closing remarks
Luke Miels, CEO
Tony Wood, Chief Scientific Officer (CSO)
Hesham Abdullah, SVP, Global Head Oncology R&D
Kaivan Khavandi, SVP, Global Head Respiratory, Immunology and Inflammation
Sanjay Gurunathan, SVP, Global Head Vaccines and Infectious Disease R&D
Charlotte Allerton, SVP, Head of R&D and CSO, ViiV Healthcare
Julie Brown, CFO
Luke Miels, CEO
2
Cautionary statement regarding forward-looking statements
This presentation contains statements that are, or may be deemed to be, forward-looking statements. Forward-looking statements give the Group’s current expectations or
forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘aim’,
‘ambition’, ‘anticipate’, ‘believe’, ‘estimate’, ‘expect’, ‘intend’, ‘potential’, ‘project’, ‘plan’, ‘target’, ‘will’, and other words and terms of similar meaning in connection with any
discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future
performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and
financial results.
Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available
to the Directors on the date of this presentation. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing
Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in
any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All readers, wherever located, should take note of these disclosures.
Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise
estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those
expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under ‘Risk factors’ in the Group’s Annual Report on Form
20-F for the full year (FY) 2025 and as described on pages 48 and 49 of the Group’s Q2 2026 results press release (the “Q2 2026 Results”). Accordingly, no assurance can be
given that any particular expectation will be met, and investors are cautioned not to place undue reliance on the forward-looking statements.
A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. Core results, CER and other non-IFRS measures may be
considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and reconciliations to the
nearest IFRS measure are available in the Q2 2026 Results and the Group’s Annual Report on Form 20-F for FY 2025 and in the “Reporting definitions” slide at the end of this
presentation. GSK provides guidance and outlooks on a Core results basis only, for the reasons set out in the “Reporting definitions” slide at the end of this presentation.
All expectations, guidance and outlooks regarding future performance and the dividend should be read together with the section “Guidance and outlooks, assumptions and
cautionary statements” on pages 52 and 53 of the Q2 2026 Results, the statements on page 328 of the Group’s Annual Report for FY 2025 and the “Basis of preparation and
assumptions” and “Reporting definitions” slides at the end of this presentation.
3
28 July 2026
Q2 2026 Results
gsk.com
Q2 2026: strong sales performance and core earnings delivery
Sales
£8.4bn
Core operating profit
£2.8bn
Core EPS
50.5p
+5%
+7%
+9%
Cash generated from
operations YTD
Dividend per share
Responsible business rating1
£4.3bn
17p
On track
2026 guidance*: Sales & operating profit specified at the upper half of range, EPS at the lower half
Absolute values at AER; percentages are growth rates at CER, unless stated otherwise. *2026 Guidance: Sales +3-5%, Operating Profit +7-9%, EPS +7-9%
- Information on the 2025 Responsible Business Performance Rating can be found at GSK's Responsible Business Report 2025 (published March 2026).
5
Q2 growth driven by Specialty Medicines and Vaccines
Total Group
£8.4bn, +5%
Specialty Medicines
£3.8bn, +14%
Vaccines
£2.3bn, +8%
General Medicines
Q2 key sales drivers
US
Europe
International
Incremental Growth (£m) / CER Growth %
Arexvy
Nucala
Cabenuva
Dovato
Meningitis
Jemperli
Benlysta
Ojjaara
Apretude
Blenrep
Shingrix
Exdensur
Trelegy
Other vaccines
Other specialty
Gen Meds excl. Trelegy -9%
£2.3bn, -9%
Absolute values at AER; percentages are growth rates at CER, unless stated otherwise.
-150
+>100%
+23%
+13%
+33%
+21%
+27%
+11%
+36%
+39%
+>100%
+3%
-7%
-7%
-11%
-100
-50
0
50
100
150
£m
6
Key launches delivering growth
Nucala (£610m +23%)
New to brand US patient volume1
(all Nucala indications)
Exdensur (£18m)
Blenrep (£36m)
US new patient starts source of business1
3,600
UK 2L MM treatment count2
Switch from
other classes
3,100
17%
2,600
Switch
from IL-5
2,100
1,600
BlenrepVd (D7)
27%
1,100
DaraVd
KRd
Bio-naive
600
56%
100
SelinexorVd
Kd
• Strong global growth driven by successful
COPD* launch and halo effect
• US (+35%): New to brand patients up 69% vs
LY, COPD patients driving ~72% of growth
• International (+18%): China #1 biologic across
all indications with 52% in COPD bio-naïve
• Steady launch focused on building access
• J-code effective 1 July reduces administrative
burden, provides HCP certainty
• >50% of patients with insurance
(Commercial/Medicare) now have coverage
• ~70% eligible patients not on biologic
Absolute values at AER; percentages are growth rates at CER, unless stated otherwise. COPD: chronic obstructive pulmonary disease *Nucala is indicated for COPD with an eosinophilic phenotype.
- IQVIA Source of Business 2. 2L NHSE Blueteq data presented in the DVRd 1L TE NICE appraisal committee meeting 2 (ACM2), 12th March 2026
• Approved in 49 countries with reimbursement
in 21 including Germany and Spain in Q2
• Launch focused on building HCP confidence
and seamless access in community
• >70% US prescribers state positive 1st
experience and highly likely to continue
• J-code effective 1 July
7
Long-acting portfolio powers HIV growth and market
share increase
£593m
£140m
£442m
£72m
• Dovato: £749m (+13%)
£453m
+31%
+38%
£341m
+73%
£245m
• Cabenuva: £453m (+33%)
• Apretude: £140m (+39%)
£101m
£317m
HIV: £2,078m (+10%)
Competitive execution drives market transition to LAIs
• 80% of HIV growth driven by LAI portfolio
• 35% total US HIV sales from LAIs
• 77% Cabenuva product switches in US from competitors1
Q2 2024
Apretude
Q2 2025
Cabenuva
LAI: long-acting injectable 1. IQVIA Jun-26
Absolute values at AER; percentages are growth rates at CER, unless stated otherwise.
Q2 2026
2026 sales growth guidance update: high-single digit % growth
Absolute sales £m
8
28 July 2026
Q2 2026 Financial
Performance
gsk.com
Note: In this section some figures may not sum due to rounding.
Strong quarter with leverage and improved productivity
Core results
Q2 2025 Q2 2026
£m
£m
AER
%
CER
%
+60bps
0.0%
Sales
7,986
8,409
5
5
Cost of sales
(1,986)
(1,898)
-4
-6
Gross profit
6,000
6,511
9
9
Gross profit margin
75.1%
77.4%
SG&A
(2,093)
(2,194)
5
5
Research and development
(1,522)
(1,721)
13
13
Royalties
246
204
-17
-17
Operating profit
2,631
2,800
6
7
Operating profit margin
32.9%
33.3%
+40bps
+60bps
Earnings per share
46.5p
50.5p
9
9
• Gross margin benefitted from product mix & LY comparator
• SG&A +5% driven by the phasing of spend
• R&D +13% driven by accelerated pipeline investment
• Royalties declined due to IP settlement in 2025
+230bps +250bps
Q2 2025
Q2 2026
AER
CER
£m
£m
%
%
Total operating profit
2,023
481
-76
-75
Total operating profit margin
25.3%
5.7%
-1960bps
-1930bps
Total earnings per share
35.5p
10.8p
-69
-69
Total results
1.4%
2.5%
0.5%
33.5%
32.9%
Q2’25
Margin
Gross
Margin
SG&A
R&D
Royalties
Q2’26
Margin
at CER
0.2%
33.3%
Currency
Q2’26
Margin
at AER
• Core EPS +9%, benefitting from buyback and tax rate
• Total results impacted by impairment of camlipixant
Core results unless stated otherwise. See page 16 of GSK’s Q2 2026 stock-exchange announcement for a full reconciliation of Total to Core results. Charts may not sum due to rounding.
10
Cash generation supporting investment in growth
Free cash flow £2.8bn, +£1bn vs H1 2025
H1 2025
H1 2026
Core operating profit
5,164
5,450
Decrease/(Increase) in working capital
(1,253)
(1,098)
Contingent consideration paid1
(668)
(749)
Other CGFO
491
653
Cash generated from operations (CGFO)
3,734
4,256
Taxation paid
(493)
(425)
Net tangible capex2
(458)
(519)
Net intangible capex2
(541)
(192)
Other3
(419)
(311)
Free cash flow (FCF)
1,823
2,809
Net debt 30 June 2026
15,132
CGFO £4.3bn;
• Working capital improvement due to lower
receivables
• Other CGFO benefitted from $130m
CureVac/BioNTech settlement
FCF £2.8bn, benefitting from:
• $400m income from linerixibat out license
• $250m special dividend related to the ViiV
Healthcare shareholding restructure*
- Nuvalent acquisition completed
on 15th July at a net cost of £7.1bn
*The extinguishment of the Put Option as part of the ViiV shareholding restructure has further strengthened GSK’s balance sheet position with credit rating agencies, providing additional capacity of ~£1bn to deploy in accordance with capital allocation priorities. The definition and reconciliation
of Core EBITDA for FY 2025 is available in the 2025 annual report. 1. Contingent consideration cash payments within CGFO primarily relate to Shionogi/ViiV 2. Net capex includes purchases less disposals of property, plant and equipment/intangibles
3. Other includes net interest paid and dividends to Non-Controlling Interests (including $250m ViiV special dividend)
11
2026 guidance
Sales
Core operating profit
Core earnings per share
3-5%
7-9%
7-9%
upper half of range
upper half of range
Product group sales growth guidance
Specialty Medicines: grow low double digits %
HIV: grow high single digits %
lower half of range
Dividend
70p
P&L modelling considerations
Gross margin: benefit from product mix & efficiencies
SG&A: broadly stable %
Vaccines: broadly stable to grow low single digit %
R&D: to grow significantly ahead of sales
General Medicines: decline mid single to low single digit %
Royalties: £850m to £900m
Operating margin: >31%*
Cash generated from operations
~£10bn*
Interest: ~£800m
Tax rate: ~17.5%
Core operating profit and Core EPS growth significantly weighted towards Q4
All guidance, outlooks, and expectations should be read together with the guidance, outlooks, assumptions, and cautionary statements in GSK’s Q2 2026 stock-exchange announcement.
*Cash generated from operations and margin guidance at 2025 actual exchange rates
Guidance updated
(see appendix for prior guidance)
12
Q2 Results and Accelerate Growth Agenda
Time
Section
Speakers
14.00 – 14.10
Q2 Results
Luke Miels, Chief Executive Officer (CEO)
Nina Mojas, President Global Product Strategy
Deborah Waterhouse, CEO, ViiV Healthcare, President Global Health
Julie Brown, Chief Financial Officer (CFO)
14.10 – 14.45
Accelerate Growth Part 1
14.45 – 15.15
Q&A
15.15 – 15.35
20-minute break
15.35 – 16.20
Accelerate Growth Part 2
16.20 – 16.55
Q&A
17.00
Adjourn / drinks reception
Introduction and objectives
Accelerate late-stage R&D
Oncology
Respiratory & Hepatology
Vaccines
HIV
Accelerate Growth programme
Closing remarks
Luke Miels, CEO
Tony Wood, Chief Scientific Officer (CSO)
Hesham Abdullah, SVP, Global Head Oncology R&D
Kaivan Khavandi, SVP, Global Head Respiratory, Immunology and Inflammation
Sanjay Gurunathan, SVP, Global Head Vaccines and Infectious Disease R&D
Charlotte Allerton, SVP, Head of R&D and CSO, ViiV Healthcare
Julie Brown, CFO
Luke Miels, CEO
13
Accelerate Growth
gsk.com
Accelerate Growth
Our objectives today
Accelerate
R&D
Simplify how we
work
Update on how GSK is reallocating capital and resources
to drive change and invest in R&D
HIV
Demonstrate robust and accelerating late-stage pipeline
with defined value propositions
Vaccines
Accelerate R&D
Respiratory &
Hepatology
Confirm confidence in our ability to grow the business
with growth accelerating 2031+
Oncology
Deliver growth
Funding:
Accelerate
Growth
Closing
15
Accelerate Growth
GSK: Path to long-term growth
Accelerate
R&D
Revenue
Maintain growth and invest in
late-stage pipeline
Mid-term
Growth drivers compensate for
the loss of dolutegravir exclusivity
Long-term
Accelerate growth through
pipeline and launches
Vaccines
HIV
Incremental growth through business development
Funding:
Accelerate
Growth
Illustrative, not to scale
Respiratory &
Hepatology
Consensus
Oncology
Dolutegravir loss
of exclusivity
period
Near-term
Time
Closing
16
Accelerate Growth
Deliver growth: Focused execution with ongoing transformation to
Specialty led biopharma
Accelerate
R&D
+4%
2016-21 CAGR
Respiratory &
Hepatology
Specialty
Oncology
≥8%
2021-26 CAGR
Vaccines
HIV
2020
Other Specialty
Oncology
2025
Respiratory
HIV
Vaccines
2026e
2031+
Risk Adjusted
General Medicines
17
Closing
2016-2020 excludes Consumer Healthcare segment sales; 2021 onwards is on a continuing basis, excluding Consumer Healthcare; All excluding COVID-19 solutions. Information, definitions, reconciliations to financial measures and impact of COVID-19 solutions available in the
financial business reviews in the annual reports for 2016 to 2025. 2016-2026: Respiratory component includes respiratory biologics Nucala & Exdensur and excludes respiratory products reported within General Medicines, the Other Specialty component principally includes Benlysta and
Jesduvroq/Duvroq. The General Medicines component reflects the existing reported product grouping in place since 2022, 2016-2021 figures restated to reflect current product grouping. HIV, Oncology and Vaccines aligned to currently reported product groupings. All guidance,
outlooks, and expectations should be read together with the guidance, outlooks, assumptions, and cautionary statements in GSK’s Q2 2026 stock-exchange announcement.
Funding:
Accelerate
Growth
2016
Accelerate Growth
Deliver growth: Focus on five core therapy areas
Vaccines
Industry leading portfolio with major
Shingrix expansion opportunity
HIV
New long-acting treatments and prevention
to reshape HIV care
18
Closing
COPD: chronic obstructive pulmonary disease
Funding:
Accelerate
Growth
New growth area with significant opportunity in
liver diseases
HIV
Hepatology
Vaccines
Multiple new assets to accelerate industry
leadership in COPD
Respiratory &
Hepatology
Respiratory
Oncology
High potential precision oncology and ADC led
pipeline
Accelerate
R&D
ADC: antibody drug conjugate
Oncology
Accelerate Growth
Accelerate R&D: Pipeline review, execute BD and drive R&D output
Supplement mid-stage
Business Development
Oncology
• Validated targets, significant
Accelerate
• 3 major 2026 acquisitions:
RAPT Therapeutics,
35Pharma and Nuvalent
Vaccines
R&D
value opportunity
Respiratory &
Hepatology
Portfolio Review
• Acceleration across:
• 7 assets
• 18 indications
• 25 Phase 3 studies
Accelerate
R&D
Maximise late-stage
HIV
Advance early-stage
Funding:
Accelerate
Growth
R&D Culture
• Scientific courage
• Relocating to Cambridge and
19
Closing
vacating Stevenage
Accelerate Growth
Accelerate R&D: Transform late-stage portfolio, increasing opportunities
in Oncology, Respiratory and Hepatology
Accelerate
R&D
20+ Phase 3 trial starts
Increased from 10 Phase 3 starts
disclosed at Q1 ‘26
11 in Oncology
Vaccines
8
Acceleration across 25 Phase 3 studies
and 18 indications, comprising:
Respiratory &
Hepatology
20+
Oncology
Late-stage pipeline momentum
9 in Respiratory
7
HIV
4 in Hepatology
2024
2025
Funding:
Accelerate
Growth
1 in Vaccines
2026
Closing
20
3
dostarlimab
Rectal cancer
ROS1+ NSCLC (1L)
VH184 + VH499
2x a year LAI HIV treatment
DAP/TOM + bepirovirsen
Chronic Hepatitis B
velzatinib
GIST (1L)
efimosfermin (x2)
F4 MASH, ALD
risvutatug rezetecan (x6)
mCRPC x2, mHSPC, SCLC (1L),
NSCLC x2
mocertatug rezetecan (x5)
PROC, PSOC, HRpOC, EC x2
HS235/GSK ‘070 (x2)
PAH, PH-HFpEF
ozureprubart (x2)
Food allergy and CSU
efimosfermin
F2/F3 MASH
neladalkib
ALK+ NSCLC (1L)
depemokimab
COPD
ROS1+ NSCLC (2L)
bepirovirsen
Chronic Hepatitis B
depemokimab
EGPA
velzatinib
GIST (2L)
belantamab mafodotin
Multiple myeloma (1L)
LA IL33/GSK ‘995 (x2)
COPD, NCFB
neladalkib
ALK+ NSCLC (2L)
cabotegravir
3x a year LAI HIV prevention
cabotegravir + rilpivirine
3x a year LAI HIV treatment
risvutatug rezetecan
SCLC (2L)
dostarlimab (x2)
HNSCC, colon cancer
ULA TSLP/GSK ‘283 (x3)
Asthma, CRSwNP, COPD
2027
2028
risvutatug rezetecan
mHSPC
risvutatug rezetecan
1L NSCLC
mocertatug rezetecan
PROC (2L+)
Shingrix
MACE
risvutatug rezetecan
2L NSCLC
VH184 + VH499
2x a year LAI HIV treatment
mocertatug rezetecan
Endometrial cancer (2L+)
ULA TSLP/GSK ‘283 (x2)
Asthma
LA IL33/GSK ‘995 (x3)
COPD
LA IL33/GSK ‘995
NCFB
mocertatug rezetecan
HRpOC (1L)
ULA TSLP/GSK ‘283 (x2)
CRSwNP
ozureprubart
Food allergy
HS235/GSK ‘070
PAH
mocertatug rezetecan
PSOC (2L+)
ULA TSLP/GSK ‘283 (x2)
COPD
ozureprubart
CSU
mocertatug rezetecan
Endometrial cancer (1L)
efimosfermin (x2)
F4 MASH
DAP/TOM + bepirovirsen
Chronic Hepatitis B
4
risvutatug rezetecan
mCRPC (late line)
risvutatug rezetecan
mCRPC (chemo naive)
8
2
Respiratory
Hepatology
Other Specialty
Oncology
HIV
Vaccines
21
NSCLC: non-small cell lung cancer GIST: gastrointestinal stromal tumours PROC: platinum resistant ovarian cancer HRpOC: homologous recombination proficient ovarian cancer PSOC: platinum sensitive ovarian cancer SCLC: small cell lung cancer mCRPC: metastatic castration resistant prostate
cancer LAI: long-acting injectable MACE: major adverse cardiovascular event MASH: metabolic-dysfunction associated steatohepatitis CRSwNP: chronic rhinosinusitis with nasal polyps COPD: chronic obstructive pulmonary disease EGPA: eosinophilic granulomatosis polyangiitis mHSPC: metastatic
hormone sensitive prostate cancer CSU: chronic spontaneous urticaria NCFB: non-cystic fibrosis bronchiectasis PAH: pulmonary arterial hypertension EC: endometrial cancer HNSCC: head & neck squamous cell carcinoma ALD: alcohol-related liver disease PH-HFpEF: pulmonary hypertension in heart
failure with preserved ejection fraction
Closing
belantamab mafodotin
Multiple myeloma (1L - Quad)
20
HS235/GSK ‘070
PH-HFpEF
Funding:
Accelerate
Growth
risvutatug rezetecan
SCLC (1L)
efimosfermin
ALD
HIV
cabotegravir + rilpivirine
3x a year LAI HIV treatment
2029 and beyond
Vaccines
velzatinib
GIST (1L)
Respiratory &
Hepatology
Jideytro
2026
Phase 3
starts
MACE
Oncology
Regulatory
submissions
2
Jideytro
Shingrix
Accelerate
R&D
6
31+
Accelerate Growth
Accelerate R&D: Late-stage pipeline momentum
Accelerate Growth
Supplement the mid-stage pipeline via focused business development
Company
Asset
ozureprubart
Hepatology
efimosfermin
Oncology
velzatinib
Respiratory
ULA TSLP
Oncology
Mo-rez & Ris-rez
Respiratory
camlipixant
Oncology
Ojjaara
✓
✓
✓
✓
Ph 3s start 2027
✓
Ph 3s ongoing
✓
Ph 3s ongoing
✓
Ph 3s start in 2026
✓
Not progressing
✓
✓
✓
✓
Executed in
2026
Ph 3s ongoing
Launched
22
Closing
ULA TSLP: ultra long-acting thymic stromal lymphopoietin
✓
✓
Ph 1b ongoing
Funding:
Accelerate
Growth
Immunology
✓
Jideytro: approved
neladalkib: filed
HIV
HS235
✓
Vaccines
Respiratory
✓
Status
Respiratory &
Hepatology
neladalkib &
Jideytro
Efficacy or
tolerability gap
Oncology
Oncology
Validated
target
Accelerate
R&D
Therapy area
Accelerate Growth
Evolution of R&D culture: advancing early-stage R&D
Cambridge
University
MRC Laboratory of
Molecular Biology
Abcam
Cambridge
Movement
Surgical Hub
1000 Discovery
Drive
Future
Children’s
Hospital
Respiratory &
Hepatology
Royal
Papworth
Hospital
AstraZeneca
Discovery
Centre
Jeffrey Cheah
& Cancer
Research UK
Cambridge
Institute
Oncology
Future
Acute
Hospital
Future Cambridge
Cancer Research
Hospital
Accelerate
R&D
Heart & Lung
Research Institute
Addenbrooke’s
Hospital
Vaccines
HIV
3000 Discovery Drive
23
Closing
Based on graphic from Prologis
4000 Discovery Drive
(future development)
Funding:
Accelerate
Growth
2000 Discovery Drive
Accelerate Growth
Simplification: Driving focus, pace and accountability in R&D by
reallocating majority of £1.9bn savings to improve pipeline value
Accelerate
R&D
Oncology
Cost base impact of ‘Accelerate Growth’ programme
(as a % of sales)
Margin benefit
Respiratory &
Hepatology
Support Functions
Supply Chain
Commercial
R&D
Vaccines
Majority of savings allocated to
late-stage pipeline
HIV
Illustrative
New
Cost Base %
Funding:
Accelerate
Growth
Current Cost
Base %
Closing
24
Accelerate Growth
Accelerate growth to drive long-term value
Mid-term
2029+
Vaccines
HIV
Jideytro (2L)
Jideytro (1L)
neladalkib (2L)
bepirovirsen
3x a year HIV prevention
2027
3x a year HIV treatment
velzatinib
Ris-rez
efimosfermin
Blenrep LCI
Mo-rez
neladalkib (1L)
Jemperli LCI
2x a year HIV treatment
Shingrix LCI
Exdensur LCI
ULA TSLP
LA IL33
ozureprubart
HS235
Respiratory &
Hepatology
2028
2026
Long-term
Oncology
Regulatory submissions
Accelerate
R&D
Near-term
Funding:
Accelerate
Growth
Underpinned by growth of key commercial assets including Nucala, Exdensur, Blenrep, Jemperli, Ojjaara, Shingrix and Cabenuva
25
Closing
LCI: life cycle innovation ULA: ultra long-acting LA: long-acting
Reflects planned regulatory submissions. Jideytro regulatory submission in 2025, acquired by GSK in 2026
Accelerate R&D
gsk.com
Accelerate Growth
Accelerate R&D: Pipeline review, execute BD and drive R&D output
Supplement mid-stage
Business Development
value opportunity
• 3 major 2026 acquisitions;
RAPT Therapeutics,
35Pharma and Nuvalent
Vaccines
R&D
• Validated targets, significant
Respiratory &
Hepatology
Accelerate
Oncology
Portfolio Review
• Acceleration across:
• 7 assets
• 18 indications
• 25 Phase 3 studies
Accelerate
R&D
Maximise late-stage
HIV
Advance early-stage
Funding:
Accelerate
Growth
R&D Culture
• Scientific courage
• Relocating to Cambridge and
27
Closing
vacating Stevenage
Accelerate Growth
Accelerate R&D: Growing late-stage pipeline with greater value, speed
and effectiveness
Accelerate
R&D
Full clinical development cycle times
improved by more than 25%
Significant increase in number of
Phase 3 starts in 2026 vs 2022
20+
20+
Respiratory &
Hepatology
10
Oncology
More than double Phase 2 and 3
assets with blockbuster potential
2016-2020
7
Vaccines
-25%
2021-2025
2026
2022
2026
HIV
2022
28
Closing
Blockbuster: Ph2/3 assets with >£2bn peak year sales potential Full clinical development: Ph1 to approval median cycle times, 11.5yrs 2016-2020; 8.5yrs 2021-2025, 2020-2024 industry upper quartile based on companies spending >$2 billion in 2024 pharma R&D spend data from CMR
Clarivate Analytics, PTRS: probability of technical and regulatory success
Funding:
Accelerate
Growth
Data and technology enable faster decision making and a higher confidence portfolio (PTRS)
Accelerate Growth
Accelerate growth: Reallocation of investment in late-stage pipeline
Acceleration decisions
Asset
Trial/Indication
Accelerated
delivery
PROC
✓
Mo-rez
2L EC
1L EC
2L SCLC*
Ris-rez
1L SCLC
2L GIST*
1L GIST
ULA TSLP
2x CRSwNP
efimosfermin
Shingrix
2x F2/3 MASH*
MACE
H2 ‘26 start
✓
H2 ‘26 start
✓
✓
H2 ‘26 start
Recruiting
Recruiting
✓
H2 ‘26 start
✓
H2 ‘26 start
✓
3x COPD
2x F4 MASH
✓
Recruiting
✓
H1 ‘27 start
Recruiting
Recruiting
H2 ‘26 start
*denotes 2025 Phase 3 start. List excludes 2026 Phase 3 study starts for 3x a year HIV treatment and Blenrep 1L Quad study
PROC: platinum resistant ovarian cancer PSOC: platinum sensitive ovarian cancer OC: ovarian cancer HRpOC: homologous recombination proficient ovarian cancer EC: endometrial cancer SCLC: small cell lung cancer mCRPC: metastatic castration resistant prostate cancer
GIST: gastrointestinal stromal tumours COPD: chronic obstructive pulmonary disease CRSwNP: Chronic Rhinosinusitis with Nasal Polyps MASH: metabolic-dysfunction associated steatohepatitis MACE: Major Adverse Cardiovascular event
29
Closing
✓
H2 ‘26 start
Funding:
Accelerate
Growth
LA IL33
H2 ’26 start
✓
2x COPD
Recruiting
HIV
2x Asthma
H2 ’26 start
✓
✓
✓
H2 ’26 start
Vaccines
velzatinib
✓
mCRPC late-line
mCRPC chemo-naive
Decisions
✓
✓
Recruiting
Respiratory &
Hepatology
Senior leader
engagement
Cross functional
R&D and
Commercial/
Medical insights
1L HRpOC
✓
Phase 3 status
Oncology
2L PSOC
Accelerated
start
Accelerate
R&D
New portfolio review
process
2031 market sizes
6
Endometrial &
Ovarian - $13bn
Respiratory
COPD - $15bn
Asthma - $26bn
Hepatology
MASH - $15bn
CHB - $3bn
Vaccines
8
Lung - $72bn
Prostate - $30bn
Respiratory &
Hepatology
1
1
2
Oncology
Oncology
20+
7
Accelerate
R&D
Phase 3 trial starts 2022–2026
show changing pipeline mix
7
5
Accelerate Growth
Transforming late-stage portfolio to focus on greater patient benefit and
value opportunities
10
HIV
2023
2024
Respiratory
HIV
Hepatology
Oncology
2026
Vaccines
MASH: metabolic-dysfunction associated steatohepatitis
CHB: chronic hepatitis B. Market size sources can be found in the reference section.
30
Closing
COPD: chronic obstructive pulmonary disease
2025
Treatment - £22bn Prevention - £6bn
Funding:
Accelerate
Growth
2022
HIV
Accelerate Growth
External innovation and BD enhance pipeline and R&D effectiveness
Phase 1
Small molecule
targeting RNA
PDO technology
CDH17 ADC
MCE platform
T-cell engagers
Enhanze
technology
Cancer Vaccine
Antibody
therapeutics
AI foundation
models
ADC prostate
cancer
Phase 2
B7-H4 ADC
Phase 3
neladalkib
KITm TKI
B7-H3 ADC
NVL-330
(HER-2)
Jideytro
Oncology
Oncology
Discovery to preclinical
Accelerate
R&D
Non-exhaustive list
of BD since 2023
Ojjaara
2 siRNA products
Equity Investment
Neurodegenerative
and kidney disease
phenotyped
GenoSphere cohorts
Fibrotic disease
PDE3/4
CD19/20 T cell
engager
siRNA EMP-012
SA030
ULA TSLP
ozureprubart (IgE)
camlipixant
(P2X3)
Vaccines
Respiratory
&
Immunology
Respiratory &
Hepatology
11 options across Respiratory, Immunology & Inflammation & Oncology
HS235 (Activin)
Hepatology
AI/ML & Liver
Disease
Liver Fibrosis
HBV siRNA
efimosfermin (FGF21)
HIV
Alzheimer’s
Oligo platform
Neurodegenerative
Platform
AlphaSeq platform
T-cell engagers
Chai2 AI system
Complementing clinical pipeline
31
Closing
Enhancing Research
Funding:
Accelerate
Growth
Platforms,
technology &
multi-therapy
area
King’s College London
UK and Europe
- Access to UK 'Golden Triangle'
and key partners inc. new site on
Cambridge Biomedical Campus
- Strong European links with key
partners
University of Oxford
Imperial College London
University of Manchester
Belgium
Tsinghua University
Shanghai
China
- Access to Shanghai biotech cluster,
significant emerging innovation and
key partners
32
Closing
Select
Selectexternal
externalpartnerships
partnershipshighlighted
highlighted--not
notexhaustive
exhaustive
EMBL:European
EuropeanMolecular
MolecularBiology
BiologyLaboratory
Laboratory
EMBL:
Funding:
Accelerate
Growth
Major academic partnerships
HIV
GSK innovation hubs
Vaccines
KU Leuven
Heidelberg
Boston University
Connecticut
Gustave Roussy EMBL
Boston
Philadelphia area
University of Cambridge
Respiratory &
Hepatology
•
•
•
•
•
Oncology
Cambridge
Accelerate
R&D
East Coast, US
- Access to Boston-Cambridge
innovation corridor and key partners
Accelerate Growth
Global network of R&D hubs and academic partners to drive innovation
Accelerate Growth
Establishing UK R&D hub in Cambridge to accelerate culture evolution
Accelerate
R&D
Oncology
• Cambridge Biomedical Campus, a leading centre
for medical research and health science in Europe
Respiratory &
Hepatology
• Co-located with Cambridge University - a key
academic partner alongside Oxford University
Vaccines
• Internationally recognised research hospitals and
clinical infrastructure
• State-of-the-art, tech-enabled labs within biotech
and AI ecosystem
HIV
• Key component of a broader accelerated R&D plan
Funding:
Accelerate
Growth
Original image from Prologis and plp
33
Closing
*Cambridge-GSK
Translational
ImmunologyCollaboration;
Collaboration;
Cambridge
Immune
Ageing;
GSK-Teichmann
Lab
*Cambridge-GSK
Translational
Immunology
Cambridge
Immune
Ageing;
GSK-Teichmann
Lab
Late-stage portfolio of significant growth
opportunities and upcoming milestones
dostarlimab
Rectal cancer
ROS1+ NSCLC (1L)
efimosfermin
F2/F3 MASH
Jideytro
ROS1+ NSCLC (2L)
bepirovirsen
Chronic Hepatitis B
depemokimab
EGPA
velzatinib
GIST (2L)
neladalkib
ALK+ NSCLC (2L)
cabotegravir
3x a year LAI HIV prevention
cabotegravir + rilpivirine
3x a year LAI HIV treatment
risvutatug rezetecan
SCLC (2L)
risvutatug rezetecan
mCRPC (chemo naive)
risvutatug rezetecan
1L NSCLC
risvutatug rezetecan
2L NSCLC
VH184 + VH499
2x a year LAI HIV treatment
LA IL33/GSK ‘995 (x3)
COPD
ozureprubart
Food allergy
ozureprubart
CSU
✓
LA IL33/GSK ‘995
NCFB
risvutatug rezetecan (x6)
mCRPC x2, mHSPC, SCLC (1L),
NSCLC x2
mocertatug rezetecan (x5)
PROC, PSOC, HRpOC, EC x2
HS235/GSK ‘070 (x2)
PAH, PH-HFpEF
ozureprubart (x2)
Food allergy and CSU
neladalkib
ALK+ NSCLC (1L)
depemokimab
COPD
belantamab mafodotin
Multiple myeloma (1L)
LA IL33/GSK ‘995 (x2)
COPD, NCFB
dostarlimab (x2)
HNSCC, colon cancer
ULA TSLP/GSK ‘283 (x3)
Asthma, CRSwNP, COPD
2029 and beyond
efimosfermin
ALD
HS235/GSK ‘070
PH-HFpEF
2
HS235/GSK ‘070
PAH
4
DAP/TOM + bepirovirsen
Chronic Hepatitis B
8
Respiratory
Hepatology
Other Specialty
Oncology
HIV
Vaccines
✓ Accelerated studies
NSCLC: non-small cell lung cancer GIST: gastrointestinal stromal tumours PROC: platinum resistant ovarian cancer HRpOC: homologous recombination proficient ovarian cancer PSOC: platinum sensitive ovarian cancer SCLC: small cell lung cancer mCRPC: metastatic castrate-resistant
prostate cancer LAI: long-acting injectable MACE: major adverse cardiovascular event MASH: metabolic-dysfunction associated steatohepatitis CRSwNP: chronic rhinosinusitis with nasal polyps COPD: chronic obstructive pulmonary disease EGPA: eosinophilic granulomatosis polyangiitis
mHSPC: metastatic hormone sensitive prostate cancer CSU: chronic spontaneous urticaria NCFB: non-cystic fibrosis bronchiectasis PAH: pulmonary arterial hypertension EC: endometrial cancer HNSCC: head & neck squamous cell carcinoma ALD: alcohol-related liver disease
PH-HFpEF: pulmonary hypertension in heart failure with preserved ejection fraction
34
Closing
belantamab mafodotin
Multiple myeloma (1L - Quad)
20
risvutatug rezetecan
mHSPC
efimosfermin (x2)
F4 MASH, ALD
Funding:
Accelerate
Growth
risvutatug rezetecan
mCRPC (late line)
✓
✓
✓
2028
velzatinib
GIST (1L)
HIV
risvutatug rezetecan
SCLC (1L)
2027
DAP/TOM + bepirovirsen
Chronic Hepatitis B
Vaccines
2026
velzatinib
- rilpivirine
✓ cabotegravir
GIST (1L)
3x a year LAI HIV treatment
mocertatug rezetecan
✓ Shingrix
✓
PROC (2L+)
MACE
mocertatug rezetecan
ULA TSLP/GSK ‘283 (x2)
✓
Endometrial cancer (2L+) ✓
Asthma
mocertatug rezetecan
TSLP/GSK ‘283 (x2)
✓ ULA
✓
HRpOC (1L)
CRSwNP
mocertatug rezetecan
TSLP/GSK ‘283 (x2)
✓
✓ ULA
PSOC (2L+)
COPD
mocertatug rezetecan
(x2)
✓ efimosfermin
✓
Endometrial cancer (1L)
F4 MASH
✓
✓
✓
VH184 + VH499
2x a year LAI HIV treatment
Respiratory &
Hepatology
Phase 3
starts
2
Jideytro
MACE
Oncology
Regulatory
submissions
3
Shingrix
Accelerate
R&D
6
Accelerate Growth
31+
Oncology
gsk.com
Accelerate Growth
Significant opportunity across Oncology
Lung
NSCLC
1,475*
101*
64%
Myelofibrosis
16*
50%
Prostate
788
40%
Bladder
369*
10%
283
47*
4
30
17*
36%
5*
17%
9
521
8%
5
Pancreatic
302*
3%
7*
GIST
19
51%
4*
Ovarian
125
32%
9*
Endometrial
135
20%
4*
Addressing areas of
significant unmet need
A team with a proven track
record in oncology
Closing
36
Funding:
Accelerate
Growth
Gastric
*Double-digit
growthininpatient
patientincidence
incidencebetween
between2025
2025and
and2030
2030projected,
projected,orordouble-digit
double-digitmarket
marketsize
sizeyear-on-year
year-on-yearCAGR
CAGRbetween
between2026-2031
2026-2031
*Double
digit growth
SCLC:small
smallcell
celllung
lungcancer
cancer NSCLC:
NSCLC:non-small
non-smallcell
celllung
lungcancer
cancer GIST:
GIST:gastrointestinal
gastrointestinalstromal
stromaltumours
tumours
SCLC:
A portfolio of competitive,
high-potential assets
HIV
Gynaecological
1,073*
65
Vaccines
Head & Neck
7
9%
Multiple myeloma
Colorectal
Gastrointestinal
4%
Respiratory &
Hepatology
Prostate and
other solid
tumours
197*
2031 global market
size ($bn)
Oncology
Haematologic
SCLC
First line
5-year survival
Accelerate
R&D
2025 incidence
(patients ‘000s)
Accelerate Growth
Competitive pipeline built across solid tumours and prioritised key
malignancies
Clinical development
neladalkib
ALK+ NSCLC
Ris-rez
Prostate
Bladder
Gastrointestinal
Jemperli
Colon, rectal
velzatinib
GIST
Ris-rez
Pancreatic
Ris-rez
H&N
Sarcoma
Driver-mutation TKIs, protein
degraders, RIPTACs, and
RNA-splicing modulators
Mo-rez
Endometrial
Mo-rez
Ovarian
HNSCC: head and neck squamous cell carcinoma
37
Closing
Products in development are not yet approved for the indications shown
NSCLC: non-small cell lung cancer SCLC: small cell lung cancer MM: multiple myeloma VEXAS: vacuoles E1 enzyme X-linked auto-inflammatory, somatic syndrome LR-MDS: lower-risk myelodysplastic syndromes
GBM: glioblastoma multiforme GIST: gastrointestinal stromal tumours H&N: head and neck TKI: tyrosine kinase inhibitor RIPTACs: regulated induced proximity targeting chimeras
Funding:
Accelerate
Growth
Gynaecological
Jemperli
Endometrial
Zejula
Ovarian
Targeted small molecule
HIV
Prostate and other
solid tumours
Jemperli
HNSCC
Zejula
GBM
Haematologic
Vaccines
belantamab
MM
Blenrep
MM
Monoclonal antibody
Respiratory &
Hepatology
Ojjaara
VEXAS
Ojjaara
LR-MDS
Ojjaara
Myelofibrosis
Blenrep
MM
Antibody-drug conjugate
Ris-rez
SCLC
NSCLC
Oncology
Lung
Jideytro
ROS1+ NSCLC
Accelerate
R&D
Marketed
Accelerate Growth
Mo-rez and Ris-rez ADCs: Advancing Phase 3 programmes based on
extensive range of clinical data sets
Ovarian
Endometrial
Prostate
SCLC*
Gastric
IgG1 mAb
Bladder
Head and neck
SCLC: small cell lung cancer
NSCLC: non-small cell lung cancer
Ph 3 ongoing
Ongoing
✓
✓
Ongoing
Ongoing
Ongoing
Ongoing
38
Closing
- Has FDA Breakthrough Designation and EMA PRIME Designation
ADC: antibody-drug conjugate TOPO1i: topoisomerase 1 inhibitor IgG1 mAb: IgG1 isotype monoclonal antibody
Ongoing
✓
Ph 3 to initiate
Funding:
Accelerate
Growth
Sarcoma
Ph 3 ongoing
Ongoing
✓
Pancreatic
Ph 3 ongoing
HIV
Rezetecan
payload +
linker
✓
✓
✓
✓
GSK pivotal
programme
Vaccines
NSCLC
✓
✓
✓
✓
✓
GSK global
data
Respiratory &
Hepatology
Ris-rez
✓
✓
✓
✓
✓
Competitor
data
Oncology
Mo-rez
Partner
data
Accelerate
R&D
Proprietary TOPO1i payload
with differentiated safety profile
Indication
Accelerate Growth
Mo-rez (B7-H4): Strong efficacy signal in gynaecological cancers
55.6%
58.8%
n=18
n=17
Rina-S
Sac-TMT
Sac-gov
Puxi-Sam
FRa TOP1i
R-DXd
CDH6 TOP1i
TUB-040
NaPi2b
FRa TOP1i
TROP2 TOP1i
TROP2 TOP1i
B7-H4 TOP1i
56.1%
50%
58%
50%
30.7%
27%
47.1%
n=57
n=36
n=12
n=22
n=114
n=41
Vaccines
FRa TOP1i
Torvu-Sam
Respiratory &
Hepatology
FRa TOP1i
Sofe-M
Oncology
Mo-rez: 67% n=12
Mo-rez: 62% n=34
Rina-S
Accelerate
R&D
2L+ endometrial cancer
cORR of key ADCs
Platinum resistant ovarian cancer
cORR of key ADCs
n=51
HIV
NaPi2b: sodium-dependent phosphate transporter 2b
TROP2: trophoblast cell surface antigen 2
39
Closing
Comparisons to other ADCs are based on cross-trial observations. Rina-S/Sofe-M/Torvu-Sam/R-DXd/TUB-040/Sac-TMT/Sac-gov/Puxi-Sam: non-GSK ADCs
ADC: antibody-drug conjugate cORR: confirmed objective response rate FRa: folate receptor alpha TOP1i/TOPO1: topoisomerase 1 (inhibitor) CDH6: Cadherin-6
Funding:
Accelerate
Growth
Activity independent of B7-H4 expression level, tolerability profile consistent with TOPO1i class
Accelerate Growth
Mo-rez: Moved at pace to initiate a large-scale Phase 3 programme
Accelerate
R&D
Mo-rez accelerated Phase 3 development plan
BEHOLD-Ovarian 02
bevacizumab combination
2L+ Platinum sensitive ovarian cancer
H2 ’26 start
BEHOLD-Ovarian 03
bevacizumab combination
1L HRp ovarian cancer
H2 ’26 start
BEHOLD-Endometrial 01
monotherapy
2L+ endometrial cancer
Recruiting
BEHOLD-Endometrial 02
PD-1 combination
1L endometrial cancer
H2 ’26 start
HIV
Funding:
Accelerate
Growth
40
Closing
HRp: homologous recombination proficient
Recruiting
Vaccines
5
Phase 3 BEHOLD trials
initiating in 2026
BEHOLD-Ovarian 01
monotherapy
2L+ Platinum resistant ovarian cancer
Respiratory &
Hepatology
600
patients dosed across
BEHOLD trials
Oncology
15
months from Phase 1b
to Phase 3 start
Accelerate Growth
Ris-rez (B7-H3): An Oncology pipeline in a single asset
97
100
99
100
100
94
99
81
Broad opportunity driven
by high B7-H3 expression
Oncology
Respiratory &
Hepatology
% B7-H3 positive
Accelerate
R&D
B7-H3 is over expressed on a wide range of solid tumours
Head &
Neck
Bladder
Gastric
Pancreatic
Sarcoma
Prostate
SCLC
NSCLC
PoC: proof of concept
41
Closing
NSCLC: non-small cell lung cancer
Signal generating
Funding:
Accelerate
Growth
SCLC: small cell lung cancer
Signal
confirmation
underway
930 patients dosed with
Ris-rez in global population
across all studies
HIV
PoC established,
GSK Ph 3
initiating/recruiting
Vaccines
Early entry into SCLC and
prostate
2L+ nsq NSCLC
ARTEMIS-101
Accelerate
R&D
2L+ SCLC
ARTEMIS-001
Accelerate Growth
Ris-rez lung: Robust data provides conviction to move with pace and scale
Ris-rez accelerated Phase 3
development plan
Oncology
Respiratory &
Hepatology
EMBOLD SCLC 303
1L SCLC
H2 ’26 start
HIV
Mono 33% cORR, 7m mPFS
Combo 47% cORR, 14m mPFS
Recruiting
Funding:
Accelerate
Growth
ARTEMIS 008: Positive Phase 3 OS data in 2L SCLC
nsq NSCLC: non-squamous non-small cell lung cancer
cORR: confirmed objective response rate mPFS: median progression-free survival mOS: median overall survival
OS: overall survival BTD: breakthrough therapy designation
42
Closing
SCLC: small cell lung cancer
Vaccines
60% cORR, 6.3m mPFS, 14.9m mOS
Granted FDA BTD
EMBOLD SCLC 301
2L+ SCLC
Accelerate Growth
Ris-rez prostate: Multiple Phase 3 trials initiating H2 ‘26
Accelerate
R&D
Ris-rez accelerated Phase 3
development plan
NHA treated mCRPC
ARTEMIS-003
Oncology
H2 ’26 start
EMBOLD-Prostate-203
Phase 2 combination
mHSPC
H2 ’26 start
HIV
Funding:
Accelerate
Growth
Supported by 9 months landmark rPFS
data presented at ASCO GU
mHSPC: metastatic hormone-sensitive prostate cancer
rPFS: radiographic progression-free survival
43
Closing
cORR: confirmed objective response rate
EMBOLD Prostate-304
Phase 3 monotherapy
Chemo-naïve mCRPC
Vaccines
NHA: next-generation hormonal agents mCRPC: metastatic castration-resistant prostate cancer
ASCO GU: American Society of Clinical Oncology genitourinary cancer symposium
H2 ’26 start
Respiratory &
Hepatology
37% cORR mCRPC total population
EMBOLD Prostate-302
Phase 3 monotherapy
Late-line mCRPC
Accelerate Growth
Ris-rez: First positive Phase 3 OS B7-H3 data, with multiple PoC studies
ESMO
Oct ‘26
• Artemis-008: Positive
•
3L+ Osteosarcoma
•
•
ILD analysis
Thoracic
•
•
NSCLC 2L+
Jemperli combo
SCLC 1L PD-L1
combo
ESMO
Sep ‘27
WCLC
Sep ‘27
Gastrointestinal
Genito-urinary
Pancreatic 2L+
•
Bladder 2L+
•
Gastric 2L+
(China data)
•
Late Line
mCRPC data
(dose opt and
combos)
•
Sarcoma 2L+
Ph 3 2L SCLC TiP
HIV
•
Vaccines
• ARTEMIS-011 Ph 3 in
EMBOLD
PanTumor-101,
dose esc. in solid
tumours, dose
opt. in SCLC
Building a
differentiated
presence
ASCO
Jun ‘27
Respiratory &
Hepatology
First Ris-rez data in
a global
population
Partner data:
ELCC
Mar ‘27
Oncology
WCLC
Sep ‘26
Ph 3 in 2L SCLC - first
positive OS Ph 3 data
for any B7-H3 ADC
Accelerate
R&D
2027
H2 ‘26
Funding:
Accelerate
Growth
Ris-rez data to be presented at key scientific conferences over the next 18 months
NSCLC: non-small cell lung cancer
44
Closing
WCLC: World Conference on Lung Cancer ESMO: European Society For Medical Oncology ELCC: European Lung Cancer Congress ASCO: American Society of Clinical Oncology
OS: overall survival PoC: proof of concept SCLC: small cell lung cancer ADC: antibody drug conjugate dose esc./ opt: dose escalation / optimisation TiP: trial in progress ILD: interstitial lung disease
mCRPC: metastatic castration-resistant prostate cancer
Accelerate Growth
Precision oncology lung: Potential to transform ALK+/ROS1+ treatment
Accelerate
R&D
84+ months
ROS1+
46+ months
EGFRm
up to ~24
months
PD-1 + chemo
~9 months
17%
NSCLC: Prevalence of
driver mutations
PDUFA 27 Nov 2026
Ongoing development programme
•
•
studies and early access programme
35% of patients now recruited in neladalkib’s
ongoing 1L Ph 3 study (ALKAZAR)
45
Closing
PDUFA: Prescription Drug User Fee Act
2,700 patients already treated across clinical
Funding:
Accelerate
Growth
NSCLC: non-small cell lung cancer
neladalkib 2L
HIV
ALK+
Filing H2 ‘26
Vaccines
2%
1L mPFS
Approved 22 July 2026
Jideytro 1L
Respiratory &
Hepatology
4%
Treatment regimen
Jideytro 2L
Oncology
Extended duration of treatment driven by improved
efficacy & tolerability
Accelerate Growth
Precision oncology lung: Neladalkib and Jideytro indicate best-in-class
efficacy
ROS1+ NSCLC
neladalkib
neladalkib
lorlatinib
lorlatinib
23.8m
zidesamtinib
Jideytro
14.5m
taletrectinib
taletrectinib
6.6m
Respiratory &
Hepatology
2L+
1 prior ROS1 TKI
Oncology
Post 2nd gen TKI
Early data
show potential
to meaningfully
improve mPFS
Accelerate
R&D
ALK+ NSCLC
9.7m
mPFS
mPFS
Vaccines
neladalkib
neladalkib
91%
zidesamtinib
Jideytro
96%
HIV
1L
Promising
12+ months
duration of
response
lorlatinib
lorlatinib
70%
taletrectinib
taletrectinib
46
Closing
*Comparisons to approved therapies are based on indirect cross trial observations based on SoC Sources: Lorlatinib P2; ALKOVE-1 ASCO 2026; Alectinib Ph3 ALEX; Alectinib mDoR ; Lorlatinib Ph3 CROWN.
mPFS: median progression free survival TKI: tyrosine kinase inhibitor NSCLC: non-small cell lung cancer 12m+ DoR: duration of response of 12 months or more
12m+ DoR
Funding:
Accelerate
Growth
12m+ DoR
74%
Accelerate Growth
Precision oncology lung: Neladalkib, designed for superior tolerability,
with potential to extend duration of treatment
Accelerate
R&D
alectinib
lorlatinib
neladalkib*
Dose reduction
19%
21%
17%
Discontinuation
11%
7%
5%
Weight gain
*10%
38%
Cognitive effects
21%
Peripheral
neuropathy
34%
“Neladalkib lower rates
consistent with manageable
tolerability profile”
“Lorlatinib requires active
monitoring and management
particularly for mood effects with
caregiver implications”
18%
Oedema
17%
55%
18%
15% / 14%
17% / 14%
47% / 44%
47
Closing
*Comparisons to approved therapies are based on cross trial observations. *ALEX 5-yr update reports 10% weight gain Sources: Lorlatinib P2; ALKOVE-1 ASCO 2026; Alectinib Ph3 ALEX; Alectinib mDoR ; Lorlatinib Ph3 CROWN.
pts: patients TEAE: treatment-emergent adverse event ALT: alanine transaminase AST: aspartate aminotransferase TKI: tyrosine kinase inhibitor
“Neladalkib - largely
asymptomatic & manageable routinely monitored by ALK TKI
prescribers"
Funding:
Accelerate
Growth
1%
HIV
Vision disorder
ALT/AST increase
Physician feedback
Vaccines
4th Gen
Respiratory &
Hepatology
All grade
TEAE
3rd Gen
Oncology
% of pts
with dose
modifications
2nd Gen
Accelerate Growth
Precision oncology GIST: Velzatinib monotherapy targets key mutations
offering potentially superior activity and tolerability profile
Accelerate
R&D
Primary
Exon 11
Exon 13/14
Exon 17/18
Tolerability
Selectivity
Unmet need
Grade 3+ TRAE
33%
1L imatinib
44%*
2L sunitinib
52%
2L bezuclastinib
72%
Asset partially targets
exon or concern
Asset does not target
exon or concern
•
1L SoC unchanged in 20+yrs
•
2L SoC associated with
significant toxicity
•
US incidence ~6,500pa,
mPFS 20-30m
*TEAE, TRAE not reported
HIV
Asset targets this
exon or concern
GIST: ~80% KIT mutations
Vaccines
velzatinib
•
pa: per annum
mPFS: median progression-free survival
48
Closing
SoC: standard of care
Funding:
Accelerate
Growth
Velzatinib: next-gen TKI, inhibits all primary, and key secondary KIT mutations
Comparisons to approved therapies are based on indirect cross trial observations based on SoC
GIST: gastrointestinal stromal tumour TKI: tyrosine kinase inhibitor TEAE: treatment-emergent adverse event TRAE: treatment-related adverse event
Respiratory &
Hepatology
Exon 9
Secondary
Oncology
Gastrointestinal Stromal Tumour TKIs
Accelerate Growth
Velzatinib: 1L Phase 3 trial initiated after strong ASCO data
Accelerate
R&D
Promising clinical activity in 1L across clinically
relevant KIT mutations
Robust proof-of-concept from Ph 1 StrateGIST-1
with data from over 270 patients across lines
Oncology
Best Change in Tumour Target Lesions per mRECIST (1L)
Phase 1/1b StrateGIST-1 study
Respiratory &
Hepatology
StrateGIST-Frontline
Phase 3
1L+ GIST - monotherapy
Recruiting
HIV
Recruiting
Vaccines
StrateGIST-3
Phase 3
2L+ GIST - monotherapy
Funding:
Accelerate
Growth
61% cORR
All 1L patients had a reduction in tumour volume
mRECIST: modified response evaluation criteria in solid tumours
cORR: confirmed objective response rate
49
Closing
GIST: gastrointestinal stromal tumour
Accelerate Growth
Blenrep: Robust clinical development in key 1L patient segments
Accelerate
R&D
Multiple myeloma
patients
Unmet need
Oncology
100%
High risk not
frail
• Need for better
DREAMM-10 1L Phase 3
Triplet: Blenrep + Rd vs dara + Rd
Vaccines
• Better efficacy
• Lower burden of care
• Improved toxicity
Respiratory &
Hepatology
Standard
risk fit and
high-risk frail
myeloma control
HIV
Illustrative
PrE1005 1L Phase 3
Quad: Blenrep + VRd vs dara + VRd
Funding:
Accelerate
Growth
Standard dosing schedule: 1.9mg/kg: 3x Q8W then Q12W
Rd: lenalidomide and dexamethasone
dara: daratumumab VRd: bortezomib, lenalidomide and dexamethasone
mg/kg: milligrams per kilogram
Q8W: every 8 weeks
Q12W: every 12 weeks
50
Closing
MM: multiple myeloma
Accelerate Growth
Blenrep in 1L multiple myeloma: Triplet data indicates competitive
efficacy, step change in quality of life, and improved ocular profile
Accelerate
R&D
Ocular event rate matching 1L
expectations with 1.9 mg/kg
extended dosing schedule
Low burden of care
Oncology
Competitive efficacy vs CD38
Quads and triplets SoC
Maintenance
Every year
3
24
4
BRd
Q12W
74%
35%
Resolution of
first Grade ≥3
97%
100%
Median time
to onset, days
72
193
Grade ≥3, (%)
HIV
12
Q3/4W
Vaccines
Induction
First 6 months
Ophthalmic exam
findings**
Respiratory &
Hepatology
infusion days
DVRd
DVRd: daratumumab, bortezomib, lenalidomide and dexamethasone
mg/kg: milligrams per kilogram
Q3/4W: every 3/4 weeks
Q12W: every 12 weeks
51
Closing
*Terpos et al April 2026: phase 1-2 single arm BelaRd trial; ** Usmani et al May 2026 DREAMM-9 1L: first line
SoC: standard of care mPFS: median progression-free survival BRd: belantamab mafodotin, lenalidomide and dexamethasone
Funding:
Accelerate
Growth
101.8m projected mPFS* 1.9 mg/kg
Accelerate Growth
Oncology: High potential and competitive oncology pipeline
Accelerate
R&D
Oncology
• Accelerate entry into lung cancer, designed to address efficacy and tolerability challenges:
• Jideytro in 2L approved by FDA with expansion to 1L in 2027
• Neladalkib PDUFA date 27 Nov 2026
Respiratory &
Hepatology
• Clinical data conviction to advance ADCs into multiple pivotal programmes at pace:
• Mo-rez: strong efficacy signal in gynaecological cancer
• Ris-rez: an oncology pipeline in a single asset; first positive Phase 3 OS data for any
B7-H3 ADC, to be presented H2 ’26
Vaccines
HIV
• Opportunity to redefine standard of care for GIST patients:
• Velzatinib inhibits all key KIT mutations as a well-tolerated monotherapy
ADC: antibody-drug conjugate
OS: overall survival
GIST: gastrointestinal stromal tumour. Assets subject to ongoing clinical evaluation and regulatory approval.
52
Closing
PDUFA: Prescription Drug User Fee Act
Funding:
Accelerate
Growth
• Upside potential for Blenrep through use in earlier treatment lines
Q2 Results and Accelerate Growth Agenda
Time
Section
Speakers
14.00 – 14.10
Q2 Results
Luke Miels, Chief Executive Officer (CEO)
Nina Mojas, President Global Product Strategy
Deborah Waterhouse, CEO, ViiV Healthcare, President Global Health
Julie Brown, Chief Financial Officer (CFO)
14.10 – 14.45
Accelerate Growth Part 1
14.45 – 15.15
Q&A
15.15 – 15.35
20-minute break
15.35 – 16.20
Accelerate Growth Part 2
16.20 – 16.55
Q&A
17.00
Adjourn / drinks reception
Introduction and objectives
Accelerate late-stage R&D
Oncology
Respiratory & Hepatology
Vaccines
HIV
Accelerate Growth programme
Closing remarks
Luke Miels, CEO
Tony Wood, Chief Scientific Officer (CSO)
Hesham Abdullah, SVP, Global Head Oncology R&D
Kaivan Khavandi, SVP, Global Head Respiratory, Immunology and Inflammation
Sanjay Gurunathan, SVP, Global Head Vaccines and Infectious Disease R&D
Charlotte Allerton, SVP, Head of R&D and CSO, ViiV Healthcare
Julie Brown, CFO
Luke Miels, CEO
53
Q&A session 1/2 - GSK senior leaders available for Q&A
Luke Miels
Chief Executive
Officer
Julie Brown
Chief Financial
Officer
Tony Wood
Chief Scientific
Officer
Nina Mojas
President, Global
Product Strategy
Deborah Waterhouse
CEO, ViiV Healthcare,
President, Global Health
Hesham Abdullah
Kaivan Khavandi
Sanjay Gurunathan
Charlotte Allerton
SVP, Head of R&D and
David Redfern
CSO, ViiV Healthcare
President, Corporate
Development, ViiV Chair
George Katzourakis
Chris Sheldon
SVP, Global Head
Oncology R&D
Regis Simard
President, Global Supply
Chain
SVP, Global Head
Respiratory, I&I R&D
Ahmed Rabie
SVP Global Product
Strategy, Oncology
SVP, Global Head
Vaccines and ID R&D
Pedro Zarazaga
SVP Global Product
Strategy, Specialty
SVP Global Product
Strategy, Vaccines
SVP, Global Head
Business Development
54
Break
15.15 – 15.35
gsk.com
Q2 Results and Accelerate Growth Agenda
Time
Section
Speakers
14.00 – 14.10
Q2 Results
Luke Miels, Chief Executive Officer (CEO)
Nina Mojas, President Global Product Strategy
Deborah Waterhouse, CEO, ViiV Healthcare, President Global Health
Julie Brown, Chief Financial Officer (CFO)
14.10 – 14.45
Accelerate Growth Part 1
14.45 – 15.15
Q&A
15.15 – 15.35
20-minute break
15.35 – 16.20
Accelerate Growth Part 2
16.20 – 16.55
Q&A
17.00
Adjourn / drinks reception
Introduction and objectives
Accelerate late-stage R&D
Oncology
Respiratory & Hepatology
Vaccines
HIV
Accelerate Growth programme
Closing remarks
Luke Miels, CEO
Tony Wood, Chief Scientific Officer (CSO)
Hesham Abdullah, SVP, Global Head Oncology R&D
Kaivan Khavandi, SVP, Global Head Respiratory, Immunology and Inflammation
Sanjay Gurunathan, SVP, Global Head Vaccines and Infectious Disease R&D
Charlotte Allerton, SVP, Head of R&D and CSO, ViiV Healthcare
Julie Brown, CFO
Luke Miels, CEO
56
Respiratory &
Hepatology
gsk.com
Accelerate Growth
Respiratory and hepatology: Connected portfolio through comorbid
vascular disease, driven by shared biology
Hepatology
CRSwNP
MASH
T2 HIGH
ALD
Hep B
Asthma
Funding:
Accelerate
Growth
PAH
HIV
Pulmonary
hypertension
Vaccines
Phase 2
• bepirovirsen + dap/tom
• gatuzosiran
Respiratory &
Hepatology
Phase 1/2
• ozureprubart
• PDE 3/4
• MST1
Late-stage
• bepirovirsen
• efimosfermin
NCFB
T2 LOW
Oncology
SLD
COPD
Late-stage
• Exdensur COPD
• ULA TSLP/GSK ’283
• LA IL33/GSK ’995
• Benlysta SS ILD
Accelerate
R&D
Respiratory
Phase 1b
• HS235/GSK ’070
58
Closing
COPD: chronic obstructive pulmonary disease ULA: ultra long-acting TSLP: thymic stromal lymphopoietin LA: long-acting IL33: Interleukin-33 SS ILD: systemic sclerosis-associated interstitial lung disease PDE: phosphodiesterase MST1: Macrophage Stimulating 1
NCFB: non-cystic fibrosis bronchiectasis CRSwNP: chronic rhinosinusitis with nasal polyps T2: type 2 inflammation PAH: pulmonary arterial hypertension SLD: steatotic liver disease MASH: metabolic dysfunction-associated steatohepatitis ALD: alcohol-related liver disease
Accelerate Growth
Respiratory and hepatology: Opportunity beyond T2 – addressing
disease state driven by inflammation and fibrosis
Accelerate
R&D
T2 focused pipeline
Inflammation and fibrosis focused pipeline
T2 driven
T2 intermediate
Driven by other inflammatory risk
~80%
~80%
~30%
~20%
Non-T2
Non-T2
Food allergy
Severe
Asthma
CRSwNP
COPD
NCFB
Pulmonary
hypertension
MASH
$18bn
$2bn
$15bn
$5bn
$15bn
$15bn
3 T2 +
1 broad label
2 T2
1
1*
(0 for group 2-5)
1
Respiratory &
Hepatology
~90%
Oncology
% of T2 disease
$15bn
Vaccines
2031 market size
Advanced therapies approved
6 T2 +
1 broad label
HIV
1 T2
ozureprubart
LA IgE
CRSwNP: chronic rhinosinusitis with nasal polyps
COPD: chronic obstructive pulmonary disease
NCFB: non-cystic fibrosis bronchiectasis
LA IL33
GSK ’995
HS235
GSK ’070
MASH: metabolic dysfunction-associated steatohepatitis. * Sotatercept.
Market sizes are for 2031
efimosfermin
FGF21
59
Closing
T2: type 2 inflammation
ULA TSLP
GSK ’283
Funding:
Accelerate
Growth
Assets with the potential to address diseases across this spectrum
Accelerate Growth
COPD: High mortality disease with limited treatment options
Accelerate
R&D
~400m
3rd leading cause of death
more than lung & breast cancer combined
of biologics available
Global prevalence (million)
Deaths/yr
Advanced therapy classes
3,700,000
2
Minimal
5
with COPD
2 classes
Oncology
400
`
At. Dermatitis
129
Minimal
6
RA
18
38,000
7
Ps.arthritis
7
Minimal
6
IBD
5
41,000
6
Multiple sclerosis 3
4,700
7
HIV
43
Vaccines
Psoriasis
Respiratory &
Hepatology
COPD
Funding:
Accelerate
Growth
$15bn: COPD treatment market in 2031 (+19% vs 2026)
At.: atopic dermatitis
RA: rheumatoid arthritis
Ps.: psoriatic
IBD: inflammatory bowel disease
60
Closing
COPD: chronic obstructive pulmonary disease
Accelerate Growth
Lung
function
=
Inconsistent control,
exacerbations and
disease progression
Increasing mortality risk
Respiratory &
Hepatology
Mortality
risk
Poor
adherence
Progressive lung
function decline
Funding:
Accelerate
Growth
Earlier biologic use in asthma preserves lung function
Illustrative*
61
Closing
ULA: ultra long-acting Products in development are not yet approved for the indications shown. * Shows anticipated outcomes
depemokimab
Mortality
risk
=
depemokimab
HIV
Stabilisation of lung
function and
improved outcomes
Exacerbation 2
Vaccines
Future
Improved
adherence
due to longacting
Lung
function
Exacerbation 1
Early
biologic
use
Oncology
Today
Late
biologic
use
Accelerate
R&D
ULA medicines support adherence, early intervention and improved
outcomes
Exacerbation 2
Exacerbation 1
Exacerbation 3
Accelerate Growth
COPD: Differentiated options for patients based on disease drivers
Approved
Q1M
Endpoints
•
•
ULA TSLP
GSK ‘283
Ph 3 initiations
H2’ 26
Q6M
LA IL33
GSK ‘995
Ph 3 start
H1 ‘27
Q3M
T2 high
broad label*
earlier in disease
ENDURA: Exacerbation
reduction / disease stability
VIGILANT: first biologic studied
in early disease
T2 high
deeper effect, earlier
•
Exacerbation reduction /
disease stability
T2 intermediate
broader population
•
COPD specific cardiopulmonary
composite endpoint
•
HIV
Q6M
breadth of
biology
Vaccines
Ph 3 COPD
ongoing
Exacerbation reduction
First to show ED visit /
hospitalisation reduction
Respiratory &
Hepatology
•
Intended COPD coverage
Oncology
Dosing
Accelerate
R&D
Status
LA: long-acting
IL33: interleukin-33
Q1M: every one month
Q6M: every six months
Q3M: every three months
ED: emergency department
T2: type 2 Inflammation
62
Closing
TSLP: thymic stromal lymphopoietin
Funding:
Accelerate
Growth
COPD: chronic obstructive pulmonary disease ULA: ultra long-acting
- Broad label characterised by eosinophilic phenotype
Broad COPD
not limited to T2
Accelerate
R&D
LA IL33 – an alarmin addressing a new plane of biology to treat broader COPD
Th1, Th17
&
vascular
biology
COPD not primarily T2-driven
Respiratory &
Hepatology
IL33 – the first true T2 agnostic MoA to
help unlock the majority of COPD
Oncology
overlap
Severe Asthma ~80% T2 driven
Accelerate Growth
COPD: Primarily a non-T2 disease, unlocked by new mechanisms like IL33
TSLP Th17
Vaccines
IL5
IL4-13
TSLP
Asthma: majority of patients addressed
by targeting T2 disease
T2: Type 2 Inflammation
IL33: Interleukin-33
Th: T helper cells
MoA: mechanism of action
COPD: T2 biology not the primary driver for most patients
New mechanisms, including IL33, unlock remaining patients
TSLP: thymic stromal lymphopoietin
IL: interleukin
63
Closing
COPD: chronic obstructive pulmonary disease
•
•
Funding:
Accelerate
Growth
•
Th2 COPD
HIV
T2
biology
Most mechanisms have
focused on expansion in T2
disease for asthma and
COPD
Accelerate Growth
LA IL33: Phase 3 COPD start H1 ’27, Q3M dosing with differentiated
patient selection and outcomes
Accelerate
R&D
• Mucus, lung function, comorbid
profile
Phase 2
Non-Cystic Fibrosis Bronchiectasis
Recruiting
Phase 2 TSLP co-administration
H2 ’26 start
HIV
• COPD-specific cardiopulmonary
composite
H1 ’27 start
Vaccines
Clinical endpoints:
Phase 3 monotherapy
COPD exacerbation reduction +
cardiopulmonary outcomes
Respiratory &
Hepatology
Patient selection:
Oncology
3-months dosing frequency
Accelerated development programme
Funding:
Accelerate
Growth
64
Closing
LA: long-acting COPD: chronic obstructive pulmonary disease Q3M: every three months TSLP: thymic stromal lymphopoietin
LA: long-acting COPD: chronic obstructive pulmonary disease Q3M: every three months TSLP: thymic stromal lymphopoietin
Accelerate Growth
ULA TSLP: First in COPD, asthma and CRSwNP, Phase 3 starts in H2 ‘26
Accelerate
R&D
Oncology
Respiratory &
Hepatology
9 months acceleration
ULA TSLP/GSK ’283: 6 Phase 3 trial
starts in H2 ’26 across 3 indications
Accelerated plan to develop 3
indications simultaneously
Vaccines
COPD-1
Asthma-1
CRSwNP-1
COPD-2
Asthma-2
CRSwNP-2
HIV
6 monthly dosing frequency
Funding:
Accelerate
Growth
COPD: chronic obstructive pulmonary disease
CRSwNP: chronic rhinosinusitis with nasal polyps
65
Closing
TSLP: thymic stromal lymphopoietin
Accelerate Growth
Ozureprubart: Potential to become the leading option for food allergy
Treatment Uptake
CSU Phase 2 Data
150
100
50
-10
-15
-20
-25
Year 9
Year 8
Year 7
Year 6
Year 5
Year 4
Year 3
Phase 3
Food allergy
Initiating
H2 ’27
Phase 3
Chronic Spontaneous Urticaria
Initiating
H2 ‘27
Funding:
Accelerate
Growth
Year 2
Recruiting
HIV
-30
0
Year 1
omalizumab Q4W
PrestIgE
Phase 2b
Food allergy
Week 16
110
ozureprubart Q8W
Week 12
200
ozureprubart single dose
-5
Vaccines
US Patients (‘000s)
250
0
Week 8
risankizumab
Plaque Psoriasis
LS Mean Change in UAS7
dupilumab
lebrikizumab
Atopic Dermatitis
Respiratory &
Hepatology
omalizumab
Food Allergy
Development plan:
Phase 3 to start H2 ‘27
Oncology
Derisked Mechanism:
Phase 2 shows deep response
Accelerate
R&D
Rapid omalizumab uptake:
3m hospital/ED visits annually
Simplified, longer-acting dosing schedule including the 25% of patients not eligible for existing therapy
LS: least square
UAS7: urticaria activity score over 7 days
Q8W: every eight weeks
Q4W: every four weeks
PoC: proof of concept
ED: emergency department
66
Closing
CSU: chronic spontaneous urticaria
Accelerate Growth
HS235 (activin-trap): Best-in-class potential in pulmonary hypertension
Only disease modifying class
Potential cardiometabolic benefit
PH HFpEF
Group 1 - PAH
• Reduced bleeding risk, expand
patient population
~50K US
~Similar size to
PAH
~200K Global.
~25-50%
Funding:
Accelerate
Growth
Representation of IC50 values (nM; log scale)
Group 3 - PH with lung disease
• Protective tissue remodelling reversing inflammation
HIV
~50%
Group 2 - PH HFpEF
• Preserve muscle mass vs. fat loss
Vaccines
5yr Survival
BMP 9/10 sparing: lower bleeding risk
Respiratory &
Hepatology
of pts
PAH
Translation into clinical benefit
Oncology
Group 1
Group 2
HS235/GSK ‘070
differentiation
PoC for PAH in 2027, Ph 3 start 2028;
PoC for PH-HFpEF in 2028, Ph 3 start 2029
PoC: proof of concept
PAH: pulmonary arterial hypertension
PH-HFpEF: pulmonary hypertension due to heart failure with preserved ejection fraction
67
Closing
PH: pulmonary hypertension BMP: bone morphogenetic protein GDF: growth differentiation factor
*Assets still in development. Comparisons to approved products made on a cross trial basis
Accelerate
R&D
Large patient population with
high mortality
Accelerate Growth
Liver disease: Significant unmet need and limited treatment options
Accelerate
R&D
Chronic Hepatitis B: ~$3bn treatment market
No functional cure with finite treatment duration
•
1m deaths/year; therapies suppress but rarely cure
Respiratory &
Hepatology
MASH: ~$15bn treatment market
•
#2 cause of liver transplant in US
•
10-17x higher risk of liver-related mortality with
significant fibrosis
Vaccines
CHB, MASH, ALD
drive over 2/3 of
liver deaths
ALD: alcohol-related liver disease
#1 cause of liver transplant in the US
68
Closing
MASH: metabolic dysfunction-associated steatohepatitis
•
Funding:
Accelerate
Growth
CHB: chronic hepatitis B
No pharmacological treatment options available
HIV
ALD: ~$0.5bn treatment market
•
Oncology
•
Accelerate Growth
Bepirovirsen: First finite treatment delivering a durable functional cure
No. pts
~75m
~1.7m
0.9m
49%
30%
~44m
~0.4m
0.6m
Pts on NUC
~6m
~0.12m
~0.14m
~0.05m
~0.02m
~0.1m
•
•
HBsAg IU/ml: hepatitis B surface antigen international units per millilitre
FC: functional cure
PEG: pegylated
26%
0%
0%
bepirovirsen placebo
bepirovirsen placebo
Functional cure
Surface antigen ≤100 IU/mL
Bepirovirsen: FC durable in > 90% patients
PEG nterferon: FC 1-2%
69
Closing
NUC: nucleos(t)ide analogue
36%
Funding:
Accelerate
Growth
CHB: chronic hepatitis B
~2.6m
~0.03m
62%
HIV
HBsAg
≤1000 IU/ml
~1.5m
19%
Baseline HBsAg
≤ 1000 IU/ml
Vaccines
Diagnosed
HBsAg
1000 – 3000 IU/ml
Baseline HBsAg
≤ 3000 IU/ml
Japan
Respiratory &
Hepatology
CHB
US
Oncology
China
Accelerate
R&D
B-Well 1 + 2 outcome
Significant unserved population
Accelerate Growth
Efimosfermin: Accelerated to lead in transformative class of medicines
F4 MASH*
fibrosis improvement (pp)
16
10-12
semaglutide
14-16
19-21
efimosfermin
24
FGF21
Non-FGF21
NEBULA 1
Phase 3
F4 MASH
Recruiting
NEBULA 2
Phase 3
F4 MASH
Recruiting
ALLSTAR
Phase 2
Alcoholic Liver Disease
H2 ’26 start
MASH: metabolic dysfunction-associated steatohepatitis
pp: percentage point
BTD: breakthrough therapy designation
18
-18
70
Closing
*not head-to-head comparison: FGF data after 24-weeks; resmetirom after 52 weeks, semaglutide after 72 weeks FGF21: fibroblast growth factor 21
Recruiting
Funding:
Accelerate
Growth
Monthly dosing vs. weekly/biweekly
Antifibrotic signal observed as early as 4 weeks
Granted China BTD
ZENITH 2
Phase 3
F2-F3 MASH
HIV
-18
Recruiting
Vaccines
efruxifermin
ZENITH 1
Phase 3
F2-F3 MASH
Respiratory &
Hepatology
resmetirom
Accelerated development plan
Oncology
F2/F3 MASH*
fibrosis improvement (pp)
Accelerate
R&D
FGF21: robust MASH data
efimosfermin competitive within the class
Accelerate Growth
Respiratory and hepatology: Portfolio of transformative potential in
prevalent and serious diseases
Accelerate
R&D
• 2026 Phase 3 readout and 26 October PDUFA:
Oncology
• B-WELL 1/2: bepirovirsen, first & only finite treatment with FC (26% pts) and clinically
meaningful benefits (62% pts)
Respiratory &
Hepatology
• Pipeline acceleration for differentiated assets:
Vaccines
• First six-monthly ULA TSLP for COPD – 6 Phase 3 trial starts, accelerated by >9 months
• LA IL33 with potential to unlock majority of COPD market – Phase 3 COPD trial start H1 ’27
• Potential best-in-class FGF21 efimosfermin asset to deliver on full SLD potential
HIV
• Promising mid-stage clinical pipeline:
• Ozureprubart – designed to be best-in-class for food allergy and CSU patients
LA: long-acting
IL33: interleukin-33
FGF21: fibroblast growth factor 21
SLD: steatotic liver disease
71
Closing
PDUFA: Prescription Drug User Fee Act FC: functional cure TSLP: thymic stromal lymphopoietin COPD: chronic obstructive pulmonary disease
PH: pulmonary hypertension. Assets subject to ongoing clinical evaluation and regulatory approval.
Funding:
Accelerate
Growth
• HS235 – potential best-in-class activin-trap for PH, improved tolerability and potential
cardiometabolic benefits
Vaccines
gsk.com
Accelerate Growth
Broadening the protective role of vaccination
Prioritising investment for key vaccines
• mRNA flu: phase 2 data to be presented in
Q3 ‘26
19x
Return on primary benefits of
vaccine spend
HIV
Up to
Vaccines
High impact
• Arexvy: real world effectiveness evidence to
inform re-vaccination; RSV hMPV combo
clinical work underway
Respiratory &
Hepatology
Healthcare spend on vaccines
• Shingrix: exploring secondary benefits in
MACE and dementia
Oncology
0.3%
Accelerate
R&D
Low cost
Funding:
Accelerate
Growth
Opportunity to improve health longevity by preventing infectious diseases
73
Closing
MACE: major adverse cardiovascular events RSV: respiratory syncytial virus hMPV: human metapneumovirus Shingrix and Arexvy are not currently approved for indications under development
Accelerate Growth
Shingrix: Evidence building in risk reduction of dementia
Medicare
RZV vs no vaccine
Denmark: MACE and dementia risk in 162,000 adults 65+ yrs
•
Finland: dementia risk in 34,000 adults ≥76 yrs
51%
33%
2026
RZV vs PPSV23
TriNetX
RZV vs flu
TriNetX
RZV vs ZVL
MACE
readout
Dementia
readout
Dan-Zoster pRCT Denmark (open label): n=162,000
17%*
Recruitment
complete
32%
RZV vs no vaccine
Dementia
readout 2030
Hybrid RCT Finland (placebo-controlled, biomarkers): n=33,609
RZV vs no vaccine
24%
RWE: real world evidence
RZV: Recombinant Zoster Vaccine
pRCT: pragmatic randomised clinical trial
PPSV23: Pneumovax 23 ZVL: Zoster Vaccine Live EHR: electronic health records
RCTs: randomised controlled trials
74
Closing
*increase in diagnosis free time
Funding:
Accelerate
Growth
Nursing
homes EHR
2029
HIV
Optum
Recruitment
complete
18%
2028
2027
27%
Vaccines
Optum
Respiratory &
Hepatology
RZV vs no vaccine
•
Oncology
KPSC
Accelerate
R&D
Two pragmatic RCTs enrolling ~200,000 individuals
RWE shows Shingrix associated with
consistent risk reduction in dementia
Accelerate Growth
Shingrix: RWE suggests broader protective effect in MACE
Global CVD prevalence
598m
2025
1,140m
2050
Respiratory &
Hepatology
MACE
MI
MI
MI
MI/stroke
Shingrix MACE studies
16%
Vaccines
MI post-HZ
Stroke
Phase 3 MACE
Shingrix vs placebo
16,000 adults >50 years
Primary end point: Adjudicated MACE
H2 ’26 start
Dan-Zoster
pRCT: Denmark
162,000 adults >65 years
MACE / dementia trial
Recruiting:
MACE data
~2027
HIV
28%
18%
Oncology
Multiple RWE observational studies
18%
Accelerate
R&D
Shingrix associated with CV event risk reduction %
27%
Funding:
Accelerate
Growth
39%
43%
CV: cardiovascular
MI: myocardial infarction
MACE: major adverse cardiovascular events
CVD: cardiovascular disease
HZ: Herpes zoster infection
pRCT: pragmatic randomised controlled trial
75
Closing
RWE: real world evidence
Accelerate Growth
mRNA flu: Potential BIC flu vaccine for older adults, leveraging mRNA
mRNAs
57% are 65+ years
100
80
40
60
47
49
52
48
19
20
0
40
38
29
39
36
44
30
• High antigen sequence fidelity
56
36
• Agile and rapid manufacturing
Vaccines
60
Respiratory &
Hepatology
Influenza Vaccine effectiveness (VE) is variable and
ranges from 20% to 60%
• Haemagglutinin
• Neuraminidase
Oncology
710k flu related hospitalisation in 2024-25 (US)
Accelerate
R&D
mRNA to improve flu Vx effectiveness
Highest influenza burden of disease in older adults
• Unique multi-antigen vaccine
composition
HIV
• Potency of immune responses
Funding:
Accelerate
Growth
mRNA-flu seasonal Phase 2 data to be presented at Options XIII conference
BIC: best in class
Vx: vaccine
76
Closing
mRNA-flu/COVID-19 Phase 1 study ongoing
Accelerate Growth
Vaccines: expanding the protective role of immunisation for older adults
Accelerate
R&D
• Our broad vaccines portfolio in older adults gives us deep knowledge and expertise
Oncology
Respiratory &
Hepatology
• Investing in strong clinical outcomes data, combined with a deeper understanding of underlying biology
and mechanism of action, could support future labels to expand benefits
Vaccines
• LCI for Shingrix builds on a growing body of evidence to support opportunities to increase global
vaccination rates to help >200m individuals in the next decade
HIV
• mRNA Flu seasonal Phase 2 data to be presented at Options XIII conference
Funding:
Accelerate
Growth
77
Closing
LCI: lifecycle innovation. Assets subject to ongoing clinical evaluation and regulatory approval
HIV
gsk.com
Accelerate Growth
HIV market value rapidly shifting from daily orals to LAIs
Accelerate
R&D
Global HIV treatment market size (2025-2035)
US HIV prevention market value (2025-2035)
Oncology
~£25bn
~£22bn
~£22bn
Respiratory &
Hepatology
~£6bn
2031
2035
Vaccines
~£6bn
~£3bn
Weekly oral
2031 and 2035 market value excludes IRA impact
Generic oral
2025
LAI
Branded oral
Generic oral
79
Closing
LAI: long-acting injectable
Branded daily oral
2035
Funding:
Accelerate
Growth
LAI
2031
HIV
2025
Accelerate Growth
Leading with innovation to end the HIV epidemic
Long-acting injectables
Treatment: monthly complete
injectable for self-admin
Multiple options
Treatment: 2x a year
VH184 + VH499
Treatment: weekly oral
Multiple options
Prevention: 3x a year
CAB
Prevention: 2x a year LAI
VH310
HIV
Treatment: 3x a year
CAB + RPV
Vaccines
Next wave R&D
breakthroughs
Respiratory &
Hepatology
Near term long-acting
injectable growth drivers
Oncology
Oral treatment portfolio
Accelerate
R&D
Pipeline
Marketed products
CAB: cabotegravir
RPV: rilpivirine
LAI: long-acting injectable
VH184: integrase strand transfer inhibitor
VH499: capsid inhibitor
VH310: pro-drug of cabotegravir
80
Closing
3x a year CAB + RPV for treatment and 3x a year CAB for prevention: new intra-muscular formulations
lotivibart: broadly neutralising antibody
Funding:
Accelerate
Growth
Immuno anti-retroviral therapy
lotivibart (N6LS)
Accelerate Growth
Groundbreaking innovation with LAI treatment franchise:
set to redefine future of HIV care
Accelerate
R&D
5 years Cabenuva RWE shows effectiveness and
durability in routine care across broad populations
LATITUDE study with Cabenuva shows superiority
in addressing adherence vs oral SoC
Oncology
✓ Robust efficacy
Respiratory &
Hepatology
OPERA study: high real-world effectiveness and low
virological failure compared to BIC/TAF/FTC
✓ High barrier to resistance
Rare clinical resistance
Vaccines
✓ Persistence
BEYOND study: 97% observed effectiveness
at 2 years
HIV
✓ Preference
Funding:
Accelerate
Growth
Multiple studies: >90% preference for Cabenuva